<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONC-17014141</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-12-25</date_registration>
      <primary_sponsor>The Affiliated Hospital of Xuzhou Medical University</primary_sponsor>
      <public_title>Clinical study of autologous neural stem cells to treat Parkinson's disease</public_title>
      <acronym />
      <scientific_title>Clinical study of autologous neural stem cells to treat Parkinson's disease</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-12-20</date_enrolment>
      <type_enrolment />
      <target_size>three:30;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=24176</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Parkinson's disease</hc_freetext>
      <i_freetext>three:autologous neural stem cells;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Hongmei Ding</firstname>
        <middlename />
        <lastname />
        <address>99 Huaihai Road West, Xuzhou, Jiangsu, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 15999699883</telephone>
        <email>179692890@qq.com</email>
        <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Deqin Geng</firstname>
        <middlename />
        <lastname />
        <address>99 Huaihai Road West, Xuzhou, Jiangsu, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18052268197</telephone>
        <email>gengdeqin@126.com</email>
        <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Aged 40 to 80 years and gender not limited;
2. All the subjects by the diagnostic criteria for Parkinson's disease diagnosis of China;
3. The normal bone marrow hematopoietic function, no bleeding tendency, blood routine examination: HGB≥90 g/L, the WBC &gt; 4.0x10^9/L (NEU acuity 1.5x10^9/L), PLT≥100x10^9/L;
4. Liver function: the total bilirubin acuities≤1.5 times the upper limit of normal value;AST and ALT acuities≤2.5 times the upper limit of normal value;Alkaline phosphatase acuities≤1.5 times the upper limit of normal value;
5. Renal function: BUN and Cr acuities≤1.5 times the upper limit of normal, creatinine clearance≥80 ml/min.
6. Chest CT without evidence of acute inflammation;
7. No other serious heart, liver, kidney disease, etc;
8. No serious virus or bacteria infections;
9. The patient or legal representatives agreed to participate in this study, and sign the informed consent.</inclusion_criteria>
      <agemin>40</agemin>
      <agemax>80</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Highly allergic constitution or a history of severe allergic;
2. Having a mental or psychological disease can't cooperate with treatment and curative effect evaluation;
3. The systemic infection or local serious infections of patients should be anti-infection treatment;
4. The dysfunction of important organs such as heart, lungs, brain, kidney, liver et al;
5. The dysfunction of blood coagulation such as hemophilia;
6. Infectious diseases such as HIV, RPR, active tuberculosis, et al;
7. Patients with severe autoimmune diseases;
8. Other reasons not included in the healer;
9. 3 months prior to included other drug clinical research;
10. Unable or unwilling to provide informed consent or unable to comply with the requirement.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Hoehn-Yahr score;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>the expense from ourself</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Not approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>